HMGB1早期预测重症急性胰腺炎患者发生PICS的价值研究

李彩霞, 孟文勤, 郝颖楠, 等. HMGB1早期预测重症急性胰腺炎患者发生PICS的价值研究[J]. 临床急诊杂志, 2022, 23(12): 859-862. doi: 10.13201/j.issn.1009-5918.2022.12.011
引用本文: 李彩霞, 孟文勤, 郝颖楠, 等. HMGB1早期预测重症急性胰腺炎患者发生PICS的价值研究[J]. 临床急诊杂志, 2022, 23(12): 859-862. doi: 10.13201/j.issn.1009-5918.2022.12.011
LI Caixia, MENG Wenqin, HAO Yingnan, et al. Value of HMGB1 in early prediction of PICS in severe acute pancreatitis patients[J]. J Clin Emerg, 2022, 23(12): 859-862. doi: 10.13201/j.issn.1009-5918.2022.12.011
Citation: LI Caixia, MENG Wenqin, HAO Yingnan, et al. Value of HMGB1 in early prediction of PICS in severe acute pancreatitis patients[J]. J Clin Emerg, 2022, 23(12): 859-862. doi: 10.13201/j.issn.1009-5918.2022.12.011

HMGB1早期预测重症急性胰腺炎患者发生PICS的价值研究

  • 基金项目:
    内蒙古自治区自然科学基金(No:N2015-1342)
详细信息

Value of HMGB1 in early prediction of PICS in severe acute pancreatitis patients

More Information
  • 目的 探讨血清高迁移率族蛋白B1(HMGB1)预测重症急性胰腺炎(SAP)患者发生持续炎症反应-免疫抑制-分解代谢综合征(PICS)的价值。方法 选取2018年1月—2020年12月内蒙古自治区人民医院收治的SAP患者141例,根据是否发生PICS将患者分为PICS组(n=39)和无PICS组(n=102)。酶联免疫吸附试验检测入院24 h、48 h、7 d、14 d时血清HMGB1表达水平。PICS影响因素分析采用logistic多因素分析;采用受试者工作特征曲线(ROC)分析HMGB1预测PICS的价值,计算曲线下面积(AUC)、灵敏度和特异度。结果 PICS组患者入院24 h、48 h、7 d、14 d时血清HMGB1表达水平均高于无PICS组(P < 0.05)。logistic多因素分析结果显示,APACHE Ⅱ评分、C-反应蛋白水平、HMGB1入院24 h水平、HMGB1入院48 h水平为SAP患者发生PICS的独立影响因素(P < 0.05)。HMGB1入院24 h水平预测SAP患者发生PICS的AUC为0.940,灵敏度为92.05%、特异度为91.47%;HMGB1入院48 h水平预测SAP患者发生PICS的AUC为0.785,灵敏度为80.07%、特异度为84.00%。结论 早期检测血清HMGB1水平有助于预测SAP患者发生PICS。
  • 加载中
  • 图 1  2组血清HMGB1表达水平比较

    图 2  各指标预测PICS的ROC曲线

    表 1  2组患者临床资料比较

    指标 PICS组(n=39) 无PICS组(n=102) P
    年龄/岁 46.01±6.34 45.11±5.87 >0.05
    性别(男/女) 21/18 62/40 >0.05
    病因/例 >0.05
      胆源性 19 50
      高脂血症性 14 41
      其他 6 11
    APACHE Ⅱ评分/分 12.09±1.87 10.56±1.76 < 0.05
    Balthazar CT评分/分 3.45±1.12 3.08±0.76 < 0.05
    C-反应蛋白/(mg·L-1) 167.90±64.05 132.45±53.12 < 0.05
    白细胞计数/(×109·L-1) 13.87±4.01 13.03±3.82 >0.05
    淋巴细胞计数/(×109·L-1) 0.76±0.28 0.83±0.31 >0.05
    白蛋白/(g·L-1) 32.09±5.08 33.25±6.02 >0.05
    ICU住院时间/d 21.78±4.01 17.34±1.19 < 0.05
    总住院时间/d 65.09±10.23 27.12±4.05 < 0.05
    脓毒性休克/例 15 14 < 0.05
    多器官功能衰竭/例 4 3 < 0.05
    死亡/例 5 3 < 0.05
    下载: 导出CSV

    表 2  2组血清HMGB1表达水平比较 mg/L,X±S

    指标 PICS组(n=39) 无PICS组(n=102) P
    HMGB1
      24 h 18.67±1.24 16.20±1.75 < 0.05
      48 h 12.97±2.10 11.03±1.87 < 0.05
      7 d 10.08±1.89 8.97±1.76 < 0.05
      14 d 7.07±1.06 5.55±0.74 < 0.05
    C反应蛋白
      24 h 167.90±64.05 132.45±53.12 < 0.05
      48 h 123.34±36.12 110.23±38.23 < 0.05
      7 d 36.89±10.01 24.89±8.23 < 0.05
      14 d 23.67±6.87 14.78±4.70 < 0.05
    下载: 导出CSV

    表 3  PICS发生的logistic多因素分析

    因素 OR 95%CI P
    APACHE Ⅱ评分 1.581 1.002~1.897 < 0.05
    C-反应蛋白 1.123 1.021~1.907 < 0.05
    HMGB1入院24 h水平 1.897 1.210~2.765 < 0.05
    HMGB1入院48 h水平 1.209 1.008~1.786 < 0.05
    下载: 导出CSV

    表 4  各指标预测PICS的效能分析

    指标 AUC 95%CI 灵敏度/% 特异度/%
    HMGB1入院24 h水平 0.940 0.918~0.998 92.05 91.47
    APACHE Ⅱ评分 0.853 0.781~0.971 85.93 84.03
    C-反应蛋白 0.821 0.782~0.934 82.96 87.20
    HMGB1入院48 h水平 0.785 0.668~0.945 80.07 84.00
    下载: 导出CSV
  • [1]

    方琦, 陶京, 常剑. 重症急性胰腺炎持续炎症-免疫抑制-分解代谢综合征的诊断与治疗研究进展[J]. 中华消化外科杂志, 2019, 18(7): 701-704. doi: 10.3760/cma.j.issn.1673-9752.2019.07.016

    [2]

    Mankowski RT, Anton SD, Ghita GL, et al. Older adults demonstrate biomarker evidence of the persistent inflammation, immunosuppression, and catabolism syndrome(PICS)after sepsis[J]. J Gerontol A Biol Sci Med Sci, 2021, 77(1): 188-196.

    [3]

    Zhao JJ, Sun TL, Wu SD, et al. High mobility group box 1: an immune-regulatory protein[J]. Curr Gene Ther, 2019, 19(2): 100-109. doi: 10.2174/1566523219666190621111604

    [4]

    Yang H, Wang HC, Andersson U. Targeting inflammation driven by HMGB1[J]. Front Immunol, 2020, 11((10)): 484.

    [5]

    Li L, Lu YQ. The regulatory role of high-mobility group protein 1 in sepsis-related immunity[J]. Front Immunol, 2021, 11: 601815. doi: 10.3389/fimmu.2020.601815

    [6]

    中华医学会消化病学分会胰腺疾病学组, 中华胰腺病杂志编辑委员会, 中华消化杂志编辑委员会. 中国急性胰腺炎诊治指南(2019年, 沈阳)[J]. 中华消化杂志, 2019, 39(11): 721-730. doi: 10.3760/cma.j.issn.0254-1432.2019.11.001

    [7]

    Bahtouee M, Eghbali SS, Maleki N, et al. Acute Physiology and Chronic Health Evaluation Ⅱ score for the assessment of mortality prediction in the intensive care unit: a single-centre study from Iran[J]. Nurs Crit Care, 2019, 24(6): 375-380. doi: 10.1111/nicc.12401

    [8]

    Taydas O, Unal E, Karaosmanoglu AD, et al. Accuracy of early CT findings for predicting disease course in patients with acute pancreatitis[J]. Jpn J Radiol, 2018, 36(2): 151-158. doi: 10.1007/s11604-017-0709-9

    [9]

    Komara NL, Paragomi P, Greer PJ, et al. Severe acute pancreatitis: capillary permeability model linking systemic inflammation to multiorgan failure[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(5): G573-G583. doi: 10.1152/ajpgi.00285.2020

    [10]

    Sendler M, van den Brandt C, Glaubitz J, et al. NLRP3 inflammasome regulates development of systemic inflammatory response and compensatory anti-inflammatory response syndromes in mice with acute pancreatitis[J]. Gastroenterology, 2020, 158(1): 253-269. e14. doi: 10.1053/j.gastro.2019.09.040

    [11]

    Mira JC, Brakenridge SC, Moldawer LL, et al. Persistent inflammation, immunosuppression and catabolism syndrome[J]. Crit Care Clin, 2017, 33(2): 245-258. doi: 10.1016/j.ccc.2016.12.001

    [12]

    Darden DB, Brakenridge SC, Efron PA, et al. Biomarker evidence of the persistent inflammation, immunosuppression and catabolism syndrome(PICS)in chronic critical illness(CCI)after surgical sepsis[J]. Ann Surg, 2021, 274(4): 664-673.

    [13]

    Zhong M, Pan TT, Sun NN, et al. Early prediction for persistent inflammation-immunosuppression catabolism syndrome in surgical sepsis patients[J]. Int J Gen Med, 2021, 14: 5441-5448. doi: 10.2147/IJGM.S331411

    [14]

    Yang N, Li BQ, Ye B, et al. The long-term quality of life in patients with persistent inflammation-immunosuppression and catabolism syndrome after severe acute pancreatitis: a retrospective cohort study[J]. J Crit Care, 2017, 42: 101-106. doi: 10.1016/j.jcrc.2017.07.013

    [15]

    Downes KJ, Barreto EF. Estimating renal function for drug dosing in critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome[J]. Intern Emerg Med, 2021, 16(7): 1751-1753. doi: 10.1007/s11739-021-02770-4

    [16]

    Zhang JL, Luo WC, Miao CH, et al. Hypercatabolism and anti-catabolic therapies in the persistent inflammation, immunosuppression, and catabolism syndrome[J]. Front Nutr, 2022, 9: 941097. doi: 10.3389/fnut.2022.941097

    [17]

    刘东全, 胡金龙, 李敏, 等. 简易PICS评分在评价急性胰腺炎严重程度中的价值[J]. 重庆医学, 2021, 50(11): 1852-1856, 1861. doi: 10.3969/j.issn.1671-8348.2021.11.012

    [18]

    Yang H, Andersson U, Brines M. Neurons are a primary driver of inflammation via release of HMGB1[J]. Cells, 2021, 10(10): 2791. doi: 10.3390/cells10102791

    [19]

    Lee JH, Song WJ, An JH, et al. Role of serum high-motility group box-1(HMGB1) concentration as a prognostic factor in canine acute pancreatitis: a pilot study[J]. Res Vet Sci, 2021, 141: 26-32. doi: 10.1016/j.rvsc.2021.09.013

    [20]

    Gao YZ, Wang LM, Niu ZQ, et al. miR-340-5p inhibits pancreatic acinar cell inflammation and apoptosis via targeted inhibition of HMGB1[J]. Exp Ther Med, 2022, 23(2): 140.

    [21]

    Ye LS, Zhang Q, Cheng YS, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+regulatory B cell expansion[J]. J Immunother Cancer, 2018, 6(1): 145. doi: 10.1186/s40425-018-0451-6

    [22]

    Watanabe H, Son M. The immune tolerance role of the HMGB1-RAGE axis[J]. Cells, 2021, 10(3): 564. doi: 10.3390/cells10030564

    [23]

    苏兆亮, 张永健, 倪萍, 等. 重组高迁移率族蛋白1(rHMGB1)体外诱导小鼠骨髓细胞向髓源性抑制性细胞(MDSC)分化[J]. 细胞与分子免疫学杂志, 2016, 32(10): 1362-1365, 1371. https://www.cnki.com.cn/Article/CJFDTOTAL-XBFM201610014.htm

  • 加载中

(2)

(4)

计量
  • 文章访问数:  685
  • PDF下载数:  87
  • 施引文献:  0
出版历程
收稿日期:  2022-09-16
刊出日期:  2022-12-10

目录